CLOCK Genes and Circadian Rhythmicity in Alzheimer Disease by Thome, J. et al.
SAGE-Hindawi Access to Research
Journal of Aging Research
Volume 2011, Article ID 383091, 4 pages
doi:10.4061/2011/383091
Review Article
CLOCKGenes and Circadian Rhythmicity in Alzheimer Disease
J. Thome,1 A. N. Coogan,2 A. G.Woods,3 C. C. Darie,3 and F. Ha¨ßler4
1Department of Psychiatry, University of Rostock, Gehlsheimerstraße 20, 18147 Rostock, Germany
2Department of Psychology, National University of Ireland, Maynooth, Maynooth, Ireland
3Biochemistry and Proteomics Group, Department of Chemistry and Biomolecular Science, Clarkson University,
Potsdam, NY 13699, USA
4Department of Child and Adolescent Psychiatry and Neurology, University of Rostock, 18147 Rostock, Germany
Correspondence should be addressed to J. Thome, johannes.thome@med.uni-rostock.de
Received 2 August 2011; Accepted 16 August 2011
Academic Editor: Aurel Popa-Wagner
Copyright © 2011 J. Thome et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Disturbed circadian rhythms with sleep problems and disrupted diurnal activity are often seen in patients suffering fromAlzheimer
disease (AD). Both endogenous CLOCK genes and external Zeitgeber are responsible for the maintenance of circadian rhythmicity
in humans. Therefore, modifications of the internal CLOCK system and its interactions with exogenous factors might constitute
the neurobiological basis for clinically observed disruptions in rhythmicity, which often have grave consequences for the quality of
life of patients and their caregivers. Presently, more and more data are emerging demonstrating how alterations of the CLOCK
gene system might contribute to the pathophysiology of AD and other forms of dementia. At the same time, the impact of
neuropsychiatric medication on CLOCK gene expression is under investigation.
1. Introduction
Alzheimer disease (AD) is the most frequent form of demen-
tia and one of the most devastating psychiatric disorders,
with an estimated 33.9million people worldwide affected [1].
With increasing life expectancy, AD prevalence will further
rise dramatically within the next decades. While the typical
neuropathological features have been well known since their
first description in 1906 [2], the complex pathophysiology
of this condition is still not fully understood. Some progress
has been made in elucidating possible risk genes [3, 4] as
well as the role of advanced glycation end products [5, 6],
amyloid plaques [7], neurofibrillary tangles [8], and other
pathological factors which probably interact within the so-
called “pathogenic cascade” [9]. Further, presently available
treatment strategies are not sufficient and not satisfying as
they, at best, slow down the progression of the symptoms but
do not provide an option to reverse them. Intervention may
frequently occur at advanced stages of neurodegeneration
which are no longer possible to alleviate [10]. Additionally,
treatments are often associated with a plethora of side effects.
From a clinical point of view, patients, their families,
carers, and health professionals are confronted with severe
challenges in managing the condition. One such typical
challenge is the disturbed diurnal-nocturnal rhythm of
many Alzheimer patients [11–13]. Interestingly, circadian
CLOCK gene polymorphisms might be linked to sleep-wake
disturbances in Alzheimer patients, although the authors
of a recent paper focusing on this hypothesis reported
largely negative findings for the 122 circadian-related poly-
morphisms included [14]. The molecular and cellular basis
of circadian rhythmicity consists of a complex interaction
between various transcription factors, commonly described
as CLOCK genes, which represent an internal timekeeping
system that interacts with external synchronising factors: the
so-called Zeitgebers [15, 16]. Via this interaction, humans
and many animals maintain a recurring 24-hour (circadian)
system for a plethora of biological and behavioural processes.
Desynchronisation can be caused by various factors such as
shiftwork, airtravelling through time zones, substances and
medication, and neuropsychiatric disorders [17, 18].
Severe desynchronisation is regularly observed in
patients suffering from AD and, therefore, the elucidation of
the role of CLOCK genes in this condition might contribute
to a significantly improved understanding of its underlying
pathomechanisms.
2 Journal of Aging Research
2. Sleep and Circadian Rhythmicity in
Alzheimer Patients
Nocturnal sleep disturbance is often reported by caregivers
of Alzheimer patients and seems to be associated with
disease severity [19]. Additionally, sleep quality is often
very poor [20] and AD patients suffering from apathy
seem to exhibit less consolidated nocturnal sleep [21].
Furthermore, disturbed sleep patterns in patients can have
adverse consequences for the health of caregivers [22].
Interestingly, a delayed endogenous circadian phase of
core body temperature was found in patients with probable
AD by Harper and coworkers [13]. The same group also
described that the deviation from normal circadian rhyth-
micity increases with the severity of Alzheimer pathology
[23] and that there might be distinct differences in the
pattern of desynchronisation depending on the type of
neurodegeneration [12]. These findings can be interpreted
as support for the hypothesis that disturbed circadian
rhythmicity in patients with AD is mediated by pathological
CNS (central nervous system) changes.
Hatfield et al. [23] monitored rhythmicity via actigra-
phy and cortisol determination in a group of mildly and
moderately demented Alzheimer patients over the course
of a year and report that as disease progresses, so does
the activity rhythm, but the cortisol rhythm is relatively
spared. These findings suggest that in the earlier stages of
the disease process, circadian deterioration may not be a
global phenomenon, but may affect specific domains. A
recent study by Hu et al. [24] shows that AD attenuates
the scale invariance of the motor rhythm, perhaps reflect-
ing pathological alterations in the SCN (suprachiasmatic
nucleus). Such pathological changes in the SCN have been
noted in postmortem analysis of the brains from severely
demented patients, with neuronal loss and tangles noted,
but rarely plaques in the SCN [25]. There are also decreases
in specific neurochemical phenotypes in the SCN that are
lost [25, 26], with such neurochemicals (VIP (vasoactive
intestinal peptide), AVP (arginine-vasopressin)) being cru-
cially implicated in SCN function. Such disturbances in
SCN function and the resultant circadian abnormalities are
postulated to in part underpin “sundowning” in Alzheimer
patients, in which behavioural agitation arises in the late
afternoon/evening [27]. In this context, the results of an
animal model experiment are interesting: the study involved
the implantation of genetically modified, beta/A4-expressing
cells into the SCN of adult rats. It was possible to demon-
strate that such overexpression of beta/A4 amyloid led to
significant alterations in the activity pattern of the animals
and disruption of circadian rhythmicity [28]. The 3xTg
(triple transgenic) mouse models of AD, which exhibits both
Abeta and tau neuropathology, show deteriorated circadian
organisation of locomotor behaviour, although there was
no weakening of the ability of the system to respond
appropriately to light stimulus, whilst the SCN of these
animals also showed a decrease of VIP and AVP cells [29].
Bero et al. [30] demonstrated, again in a murine model, that
the concentration of interstitial-fluid Abeta and, thus, the
Abeta aggregation depend on endogenous neuronal activity,
implying that disturbed sleep could contribute to amyloid
deposition. Craig et al. [31] suggested that the common
and distressing sleep disruption in Alzheimer patients is
associated with genetic factors, specifically with a variation
of the MAO-A (monoamine oxidase A) gene. Other obvious
candidate genes are CLOCK genes. While this gene family
has been implicated in other neuropsychiatric disorders [32],
a recent study failed to reveal possible associations between
CLOCK gene single-nucleotide polymorphisms (SNPs) and
sleep-wake disturbance in AD [14]. Nevertheless, even if
CLOCK gene variants have not yet been identified as possible
risk factors, it is possible that the expression of these genes is
altered in Alzheimer patients and that a changed expression
pattern of these genes contributes to disturbed circadian
rhythms [33].
3. The Role of CLOCKGenes in AD
It has been shown that age, the most important risk factor
for AD, influences the expression of molecules involved
in immunity as well as in cell signaling and transcription
factor regulation, such as transforming growth factor-beta
and phosphorylated SMAD3 (Mothers against decapenta-
plegic homolog 3), in the mouse suprachiasmatic (SCN)
and paraventricular nuclei, that is, the neuroanatomical
areas crucially involved in the maintenance of circadian
rhythmicity [34].
In a recent postmortem study, Cermakian and coworkers
found significant differences in the expression pattern of
CLOCK genes between Alzheimer patients and controls.
The RNA (ribonucleic acid) expression level of the CLOCK
gene PER1 (period circadian protein homolog 1), PER2
(period circadian protein homolog 2), and BMAL1 (brain
andmuscle aryl-hydrocarbon-receptor-nuclear translocator-
(ARNT-) like) were quantified via RT-PCR (reverse tran-
scription polymerase chain reaction) for the following brain
areas: bed nucleus of the stria terminalis, cingulate cortex,
and the pineal gland [33]. A previous study had already
shown that in the brain of Alzheimer patients vasopressin
gene expression is altered in the SCN [35].
Additionally, a possible noncircadian role of CLOCK
genes in psychiatric disorders has been discussed, mainly
affecting behavioural phenomena; however, this could also
be an epiphenomenon of underlying rhythmicity at the
cellular and systemic level [36].
A further important point is also the possibility of using
a “resetting” of the internal clock in the treatment of AD.
For example, there is evidence that the use of light therapy
may delay cognitive decline in AD as well as noncognitive
symptoms such as depression [37, 38].
In this context, the possible impact of AD medication on
CLOCK gene expression and, thus, indirectly on circadian
rhythmicity must also be discussed. To our knowledge, there
are no studies published which address this issue specifically
for medication used in Alzheimer treatment. However, there
is considerable evidence that neuropsychiatric medication
can significantly alter the expression of CLOCK genes in
various brain areas. In animal models, haloperidol alters the
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circadian CLOCK gene expression in the murine CNS [17].
Further, medication with typical neuroleptic haloperidol has
been found to alter the rhythmicity of rest-activity cycle and
to deteriorate the cognitive state in early-onset Alzheimer
patients [39].
4. The Dilemma of How andWhen to
Monitor the CLOCKGenes
There are significant difficulties in monitoring CLOCK
genes, either when one monitors the genes themselves or
their RNA or protein products. Starting at the gene level, it
is important to know exactly when the material was collected
during the day from patients with AD. Since the genes are
influenced by circadian rhythms, a sample collected during
the night will be different from ones collected during the day
(or even morning/evening). Finding a matched control may
also be difficult. Background substraction and data manip-
ulation to eliminate false positive or false negative results is
also important and difficult to address. It is also important to
know what is influenced by circadian rhythms: the gene, the
RNA, the protein, protein posttranslational modifications,
protein-protein interactions, or a combination of more than
one? Also, if only CLOCK proteins are responsible for the
circadian phase, what phenomenon affects the level of the
proteins per se? Is it the increase in RNA translation (and
increased gene transcription) leading to increased protein
expression or is it just prevention of protein degradation?
Is it reduced rate of phosphorylation or increased rate
of dephosphorylation? Trying to answer these and other
questions as well as finding the right way to investigate these
genes and their transcriptional and translational products, as
well as posttranslational modifications and protein-protein
interactions is challenging and time consuming.
5. Discussion
During recent years, better understanding of the molecular
and cellular basis of the clinically frequently observed sleep
disturbances and disrupted diurnal and nocturnal rhythms
of Alzheimer patients is slowly evolving. CLOCK genes are
crucially involved in the maintenance of such rhythmicity,
and studies linking this molecule family to brain and body
processes in Alzheimer patients can further elucidate the
etiopathogenesis of this most frequent dementia. However,
to date, the number of such studies is limited and there
are only very few reliable and reproducible data available.
Further research is urgently needed, especially regarding the
exact role CLOCK genes play within the AD pathological
cascade and regarding the exact interaction with other
pathogenic factors such as amyloid, neurofibrillary tangles,
oxidative stress, advanced glycation end products, lipidomic
alterations, altered immune modulation, excitotoxicity, and
so forth.
Another important feature of CLOCK genes is their close
interrelation with external, that is, environmental factors;
thus, very few other gene families exhibit such strong gene-
environment interaction and interdependency. Therefore,
they might be crucial in the integration of exogenous factors
and noxae (such as stress) and endogenous vulnerability fac-
tors (such as inherited genetic variants), ultimately leading to
the clinical phenomenology of AD.
Finally, using and applying this knowledge for the
development of improved treatment strategies with better
efficacy and tolerability will be an important challenge
which, if faced, might lead to significant contributions to
the improvement of the quality of life of millions of people
suffering from AD.
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